Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation

Liver International

Volumn 32, Issue 5, 2012, Pages 712-731

  Berenguer, Marina ^a   Charco, Ramón ^b   Manuel Pascasio, Juan ^c   Ignacio Herrero, Jose ^d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Donor; Immunosuppression; Recurrence; Survival; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; BOCEPREVIR; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PEGINTERFERON; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ASTHENIA; BILE DUCT OBSTRUCTION; CONSENSUS; DRUG EFFICACY; DRUG TOLERABILITY; ELASTOGRAPHY; FATIGUE; FOLLOW UP; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MEDICAL SOCIETY; MENTAL DISEASE; RECURRENT INFECTION; RETRANSPLANTATION; RETREATMENT; REVIEW; STEROID THERAPY; THYROID DISEASE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PROGNOSIS; RECURRENCE; REOPERATION;

EID: 84859444244     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02731.x     Document Type: Review

References (219)

1. Adam R, McMaster P, O′Grady JG, et al. Evolution of liver transplantation in Europe: report of the European liver transplant registry. Liver Transpl 2003; 9: 1231-43.
2. Sociedad Española de Trasplante Hepático y Organización Nacional de Trasplantes. Registro Español de Trasplante Hepático. Memoria de Resultados 1984-2009. Características de los Receptores Hepáticos. Diagnóstico Principal de los Receptores. Available at: Accessed 10 December 2011.
3. García-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and inmediately after liver transplantation. Hepatology 2002; 35: 680-7.
4. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation. Relationship with rejection episodes. Hepatology 1999; 29: 250-6.
5. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-8.
6. Roche B, Samuel D. Hepatitis C virus: up to the minute. Liver Transpl 2010; 16(Suppl. 2): S26-35.
7. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-6.
8. Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl 2009; 15(Suppl. 2): S35-41.
9. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-71.
10. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
11. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
12. Sociedad Española de Trasplante Hepático y Organización Nacional de Trasplantes. Registro Español de Trasplante Hepático. Memoria de Resultados 1984-2009. Resultados del Trasplante Hepático. Supervivencia del Paciente y del Primer Injerto con Cirrosis (sin Hepatocarcinoma) según Serología VHC del Receptor (Adultos/Trasplantes Electivos/1991-2009). 83-4. Available at: Accessed 10 December 2011.
13. Belli L, Burroughs A, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Traspl 2007; 13: 733-40.
14. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13: 719-24.
15. Feray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619-25.
16. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-7.
17. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-9.
18. Boker KHW, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-10.
19. Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural hystory of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15: 1872-81.
20. Moya A, Berenguer M, Aguilera V, et al. Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centres with high rates of hepatitis C? Liver Transpl 2002; 8: 1020-7.
21. Bozorgzadeh A, Orloff M, Abt P, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007; 13: 807-13.
22. Melum E, Friman S, Bjoro K, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol 2007; 47: 777-83.
23. Verna EC, De Martin E, Burra P, et al. The impact of hepatitis C and biliary complicactions on patient and graft survival following liver transplantation. Am J Transpl 2009; 9: 1398-405.
24. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-95.
25. Foxton MR, Quaglia A, Muiesan P, et al. Impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-9.
26. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome. Liver Transpl 2009; 15: 1662-70.
27. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
28. Charlton MR, Thompson AJ, Veldt BJ, et al. Interleukin-28B Polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.
29. Brocato M, Trotter JF, Forman L, et al. Genetic variation of IL-28B associated with severity of HCV recurrence following livr transplantation. AASLD 2010. Abstract poster 1158. Hepatology 2010; 52(Suppl. 4): 875A.
30. Berenguer M. Risk of extended criteria donors in hepatitis c virus - positive recipients. Liver Transpl 2008; 14: S45-50.
31. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-79.
32. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-78.
33. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
34. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28-34.
35. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41.
36. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-52.
37. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92.
38. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol 2006; 45: 483-513.
39. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl 2003; 9: S44-7.
40. Cameron AM, Ghobrial RM, Yersiz H, et al. Optimal utilization of donor grafts with extended criteria: a single center experience in over 1000 liver transplants. Ann Surg 2006; 243: 748-55.
41. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90.
42. Briceño J, Ciria R, Pleguezuelo M, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007; 39: 2297-9.
43. Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6: 407-12.
44. Briceño J, Marchal T, Padillo J, Solórzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002; 74: 522-6.
45. Watt K, Lyden E, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2005; 12: 134-9.
46. Humar A, Horn K, Kalis A, et al. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5: 399-405.
47. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9: 48-51.
48. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis. J Hepatol 2006; 45: 127-43.
49. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12: 1496-503.
50. Ballarin R, Cucchetti A, Spaggiari M, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation 2011; 91: 1265-72.
51. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US national transplant registry analysis. Transpl Int 2010; 23: 1038-44.
52. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease alter liver transplantation. Gastroenterology 1995; 108: 1088-96.
53. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. J Hepatol 2004; 41: 830-6.
54. Gane EJ, Naoumov NV, Qian JP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
55. Sreekumar R, González-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-30.
56. Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-93.
57. Papatheodoridis GV, Barton SGR, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999; 45: 427-34.
58. Shakel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15: 709-18.
59. Lyra AC, Fan X, Ramrakhiani S, Di Bisceglie AM. Evolution of hepatitis C virus quasispecies after liver transplantation. Gastroenterology 2002; 123: 1485-93.
60. Rosen HR, Sunwen C, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-6.
61. Sánchez-Fueyo A, Restrepo JC, Quintó L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56-63.
62. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transpl 2002; 2: 461-6.
63. Nebbia G, Mattes FM, Cholangitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C replication after liver retransplantation. Liver Transpl 2007; 13: 130-5.
64. Humar A, Washburn K, Freeman R, et al. Assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007; 13: 1422-7.
65. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70: 1454-8.
66. Torre-Cisneros J, Fariñas MA, Castón JJ, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735-58.
67. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients : risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066-72.
68. AlDosary AA, Ramji AS, Elliott TG, et al. Post-liver transplantation diabetes mellitus : an association with hepatitis C. Liver Transpl 2002; 8: 356-61.
69. Veldt BJ, Poterucha JJ, Watt KDS, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transpl 2009; 9: 1406-13.
70. Rosen HR, Grecht DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-82.
71. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-61.
72. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697-700.
73. Fujita S, Fujikawa T, Mizuno S, et al. Is early recurrence of hepatitis C associated with biliary anastomotic stricture after liver transplantation? Transplantation, 2007; 84: 1631-5.
74. Katz LH, Mor E, Brown M, et al. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome. Clin Transplant 2006; 20: 465-70.
75. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-74.
76. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63-6.
77. Melero JL, Berenguer M. Optimum minimization strategies in hepatitis C virus infected liver transplant. Cur Op Org Transpl 2007; 12: 641-6.
78. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258-62.
79. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-9.
80. Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12: 1464-72.
81. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-41.
82. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-7.
83. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis c virus-positive recipients. Transplantation 2010; 15: 1204-9.
84. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl. 3): S58-62.
85. Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756-63.
86. Charlton M. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Liver Transpl Surg 1999; 5: S107-14.
87. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-8.
88. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47: 793-8.
89. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE, Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-9.
90. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-95.
91. Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005; 18: 1336-45.
92. Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14: 1752-60.
93. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-35.
94. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22: 892-905.
95. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-25.
96. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 52-7.
97. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-6.
98. Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521-31.
99. Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-91.
100. Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009; 9: 1725-31.
101. Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004; 77: 562-7.
102. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123-31.
103. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132-42.
104. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620-2.
105. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-Interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-70.
106. Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011; 91: 128-32.
107. Asthana S, Toso C, Meeberg G, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28-34.
108. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-22.
109. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702-9.
110. Firpi RJ, Soldevila-Pico C, Morelli GG, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196-203.
111. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
112. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.
113. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
114. Carrión JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
115. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.
116. Jacobson IM, Mc Hutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
117. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
118. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided Telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
119. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
120. Bacon BR, Gordon SC, Lawitz EJ, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
121. Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. J Hepatol 2011; 54(Suppl. 1): S4 (abst 7).
122. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-204.
123. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707-13.
124. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-56.
125. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.
126. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.
127. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment, on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426-33.
128. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-21.
129. Walter T, Scoazec JY, Guillaud O, et al. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009; 15: 54-63.
130. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003; 9(Suppl. 3): S95-100.
131. Sheiner P, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8.
132. Singh N, Gayowski T, Wannstedt C, et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65: 82-6.
133. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001; 33: 1355-7.
134. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98.
135. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-11.
136. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transpl 2005; 5: 118-24.
137. Kuo A, Tan V, Lan B, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008; 14: 1491-7.
138. Eguchi S, Takatsuki M, Soyama A, et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. Ann Transplant 2007; 12: 11-15.
139. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
140. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
141. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
142. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010; 1: CD006803.
143. Guillouche P, Féray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163-74.
144. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247-52.
145. Samuel D, Bizollon T, Feray C, et al. Interferon-a 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-50.
146. Ross AS, Bhan AK, Pascual M, et al. Pegylated interferon a-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-73.
147. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-74.
148. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon a2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-4.
149. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-7.
150. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-a in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577-82.
151. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359-65.
152. Biselli M, Andreone P, Gramenzi A, et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27-32.
153. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-76.
154. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transpl 2006; 6: 2348-55.
155. Mukherjee S, Lyden E. Impact of pegylated interferon a-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006; 26: 529-35.
156. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-12.
157. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-7.
158. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (a-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-9.
159. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-8.
160. Zimmermann T, Bocher WO, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583-90.
161. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-17.
162. Hanouneh IA, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-8.
163. Cescon M, Grazi GL, Cucchetti A, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-9.
164. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-77.
165. Lodato F, Berardi S, Gramenzi A, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450-7.
166. Lee WC, Wu TJ, Chou HS, et al. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients. J Viral Hepat 2010; 17: 770-7.
167. Schmidt SC, Bahra M, Bayraktar S, et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci 2010; 55: 2063-9.
168. Jain A, Sharma R, Ryan C, et al. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transplant 2010; 24: 104-11.
169. Dinges S, Morard I, Heim M, et al. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009; 11: 33-9.
170. Raziorrouh B, Jung MC, Schirren CA, et al. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12. Eur J Gastroenterol Hepatol 2008; 20: 778-83.
171. Al-Hamoudi W, Mohamed H, Abaalkhail F, et al. Treatment of genotype 4 hepatitis c recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci 2011; 56: 1848-52.
172. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-46.
173. Garg V, van Heerswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-7.
174. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents. A potentially lethal cocktail. Hepatology 2011; 54: 3-5.
175. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032-8.
176. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623-9.
177. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850-8.
178. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159-65.
179. Stanca CM, Fiel MI, Kontorinis N, et al. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180-6.
180. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated Hepatitis C positive Liver transplant recipients. J Hepatol 2011; 55: 207-17.
181. Cholongitas E, Samonakis D, Patch D, et al. Dhillon A. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81: 488-90.
182. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006; 12: 827-30.
183. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56: 237-42.
184. Lodato F, Azzaroli F, Tame MR, et al. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol 2009; 15: 5449-54.
185. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 270-2.
186. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-85.
187. Coto-Llerena M, Perez-del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transpl 2011; 11: 1051-7.
188. Bizollon T, Adham M, Pradat P, et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005; 79: 325-9.
189. Feliu A, Carrión JA, Massaguer A, et al. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat 2006; 13: 544-51.
190. Kornberg A, Küpper B, Tannapfel A, et al. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study. J Gastroenterol Hepatol 2007; 22: 2135-42.
191. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181-90.
192. Berenguer M, Rayón M, Prieto M, et al. Are postransplantation protocol liver biopsies useful in the long-term? Liver Transpl 2001; 7: 790-6.
193. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003; 9: 1152-8.
194. Sebag M, Rifai K, Féray C, et al.All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003; 37: 1293-301.
195. Blasco A, Forns X, Carrión JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-9.
196. Samonakis DN, Cholangitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression afeter liver transplantation for HCV cirrhosis. Liver Transpl 2007; 13: 1305-11.
197. Carrión JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-8.
198. Rigamonti C, Donato MF, Fraquelli M, et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 2008; 57: 821-7.
199. Corradi F, Piscaglia F, Flori S, et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009; 41: 217-25.
200. Harada N, Soejima Y, Taketomi A, et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 2008; 85: 69-74.
201. Carrión JA, Torres F, Crespo G, et al. Liver stiffness identifies two different patterns PF fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34.
202. Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008; 14: 1294-302.
203. Benlloch S, Berenguer M, Prieto M, et al. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple non-invasive index. Liver Transpl 2005; 11: 456-62.
204. Benlloch S, Heredia L, Barquero C, et al. Prospective validation of a noninvasive índex for predicitng liver fibrosis in hepatitis C vírus-infected liver transplant recipients. Liver Transpl 2009; 15: 1798-807.
205. Cross TJS, Calvaruso V, Foxton MR, et al. A simple, non-invasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J Viral Hepat 2010; 17: 640-9.
206. Carrión JA, Fernández-Varo G, Bruguera M, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-58.
207. Sociedad Española de Trasplante Hepático y Organización Nacional de Trasplantes. Memoria de Resultados, 2004-2009. (Análisis univariante de supervivencia). Available at Accessed 10 December 2011.
208. Pelletier SJ, Schaubel DE, Punch JD, et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434-40.
209. Carrión JA, Navasa M, Foros X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962-70.
210. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus- related graft cirrhosis. Liver Transpl 2003; 9: 228-35.
211. Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005; 11: 1567-73.
212. Marti J, Charco R, Ferrer J, et al. Optimization of liver grafts in liver retransplantation: a European single-center experience. Surgery 2008; 144: 762-9.
213. Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection. Am J Transplant 2008; 8: 404-11.
214. Doyle HR, Morelli F, McMichael J, et al. Hepatic retransplantation - an analysis of risk factors associated with outcome. Transplantation 1996; 61: 1499-505.
215. Markmann JF, Gornbein J, Markowitz JS, et al. A simple model to estimate survival after retransplantation of the liver. Transplantation 1999; 67: 422-30.
216. Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002; 236: 315-22.
217. Azoulay D, Linhares MM, Huguet E, et al. Decision for retransplantation of the liver: an experience-and cost-based analysis. Ann Surg 2002; 236: 713-21.
218. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29: 365-70.
219. Linhares MM, Azoulay D, Matos D, et al. Liver retransplantation: a model for determining long-term survival. Transplantation 2006; 81: 1016-21.